Tower Research Capital (TRC)
BBP icon

Tower Research Capital (TRC)’s Virtus Biotech ETF BBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio BBP Stock Details BBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-35
Closed -$1K – 2703
2017
Q1 		$1K Buy
+35
New +$1.28K ﹤0.01% 2759
2016
Q4 		– Sell
-70
Closed -$2K – 3815
2016
Q3 		$2K Sell
70
-30
-30% -$926 ﹤0.01% 3028
2016
Q2 		$3K Sell
100
-48
-32% -$1.27K ﹤0.01% 3655
2016
Q1 		$4K Sell
148
-739
-83% -$18K ﹤0.01% 2852
2015
Q4 		$27K Sell
887
-141
-14% -$4.27K ﹤0.01% 978
2015
Q3 		$28K Buy
+1,028
New +$34.7K ﹤0.01% 1445
2015
Q1 		– Sell
-38
Closed -$1K – 4397
2014
Q4 		$1K Buy
+38
New +$994 ﹤0.01% 3592

Other funds holding BBP

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Virtu KCG Holdings
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Federation des caisses Desjardins du Quebec
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Tower Research Capital (TRC)'s BBP Position: Q2 2017 in Review

Tower Research Capital (TRC) sold out of Virtus Biotech ETF (BBP) in Q2 2017, closing a stake of 35 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in BBP in Q4 2014 and held it in 7 quarters. The position peaked at $28K in Q3 2015. 19 funds tracked by Wall St. Rank hold BBP as of Q2 2017.

  • Tower Research Capital (TRC) reported no remaining Virtus Biotech ETF position as of Q2 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 35 Virtus Biotech ETF shares in Q2 2017, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Virtus Biotech ETF in Q4 2014 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s Virtus Biotech ETF position peaked at $28K in Q3 2015.
  • 19 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2017, filed 15 Aug 2017.